Home>Topics>Companies>Bayer AG

Bayer AG

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
  1. BRIEF- Bayer says phase III trial of Sorafenib does not meet primary endpoint in patients with advanced breast cancer


    Fri, 25 Jul 2014

    July 25 (Reuters) - Bayer AG : * Says phase III trial of sorafenib with capecitabine does not meet primary

  2. BRIEF- Bayer says Eylea trial shows sustained improvement in vision


    Fri, 18 Jul 2014

    July 18 (Reuters) - Bayer AG : * Says two-year results from Phase III trial of Eylea eye drug show sustained improvement in vision for people with diabetic macular edema

  3. Compugen achieves first milestone in Bayer collaboration


    Mon, 7 Jul 2014

    basis for its collaboration with Bayer HealthCare ( OTCPK:BAYRY ) ( OTCPK:BAYZF ..... a $1.2M milestone payment from Bayer . The two firms formalized their ..... therapeutic antibodies developed by Bayer against the checkpoint proteins

  4. China approves Bayer deal to buy Dihon, other deals


    Fri, 4 Jul 2014

    SHANGHAI, July 4 (Reuters) - The Chinese Ministry of Commerce's anti-monopoly bureau has approved German drugmaker Bayer AG 's deal for traditional Chinese medicine (TCM) drugmaker Dihon Pharmaceutical Group Co, in a raft of deals approved on Friday.

  5. CHMP recommends label expansion for Eylea


    Fri, 27 Jun 2014

    Agency (EMA) approve Regeneron Pharmaceuticals ' ( REGN ) Eylea ( aflibercept ..... occlusion (CRVO). Regeneron and Bayer Healthcare ( OTCPK:BAYRY ) ( OTCPK ..... product in the U.S. while Bayer Healthcare has the license for exclusive

  6. BRIEF- Bayer says Eylea receives EU recommendation for diabetic macular edema


    Fri, 27 Jun 2014

    June 27 (Reuters) - Bayer AG : * Says aflibercept (Eylea) receives positive CHMP opinion for the treatment of visual impairment due to diabetic macular edema in EU

  7. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns


    Thu, 26 Jun 2014

    order to acquire Cadence Pharmaceuticals . While the deal gives ..... example, we only downgraded Bayer 's BAYRY "> BAYRY issuer ..... will significantly expand Bayer 's already well-positioned ..... material science toward Bayer 's health-care operations

  8. BRIEF- Bayer says Bayer Healthcare , Dimension Therapeutics to develop gene therapy for Hemophilia A


    Mon, 23 Jun 2014

    June 23 (Reuters) - Bayer AG : * Says Bayer healthcare and dimension therapeutics to develop novel gene

  9. BRIEF- Bayer receives approval for Nexavar in Japan for treatment of thyroid cancer


    Fri, 20 Jun 2014

    June 20 (Reuters) - Bayer AG : * Says receives approval for Nexavar (sorafenib) in Japan for treatment of

  10. BRIEF- Bayer's Xofigo attested to have considerable benefit by German reimbursement agency


    Thu, 19 Jun 2014

    June 19 (Reuters) - Bayer AG : * Says Xofigo drug attested to have considerable benefit in treating certain

« Prev12345Next »
Content Partners